prednisone has been researched along with Multiple Sclerosis in 190 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the original 2-year ASA study, 181 patients with early relapsing-remitting multiple sclerosis were randomised into 3 treatment arms: those treated with interferon beta (n=60), with interferon beta and low-dose azathioprine (n=58), and interferon beta, azathioprine and low-dose prednisone (n=63)." | 9.16 | Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. ( Dolezal, O; Havrdova, E; Horakova, D; Kalincik, T; Krasensky, J; Seidl, Z; Vaneckova, M, 2012) |
| "Isoprinosine, a drug enhancing the cellular immunity, was administered to 11 patients with multiple sclerosis (MS) for a period of 60 days." | 9.05 | Isoprinosine in multiple sclerosis treatment: a preliminary study. ( Delodovici, M; Mazzarello, P; Pinelli, P; Poloni, M; Rocchelli, B, 1982) |
| "A 38-year-old woman on treatment with dimethyl fumarate for multiple sclerosis presented with a 7-day history of weakness and fatigue." | 7.91 | The first reported case of drug-induced hemolytic anemia caused by dimethyl fumarate in a patient with multiple sclerosis. ( Carcelén-Gadea, M; Castro-Izaguirre, E; Marín, M; Quintanilla-Bordás, C, 2019) |
| "Prednisone and methylprednisolone are well absorbed orally and have lower treatment costs than IV methylprednisolone, but concern that low-dose corticosteroid may cause increased disease activity and that high oral doses may cause gastric ulceration inhibits use of oral therapy for MS attacks." | 7.70 | Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis. ( Enns, R; Hilsden, RJ; Meddings, JB; Metz, LM; Sabuda, D, 1999) |
| "The effect of large-dose prednisone therapy (3960 mg over 56 days) on IgG subclasses in the cerebrospinal fluid and sera, as well as on their intrathecal synthesis, was studied in 15 patients with clinically definite multiple sclerosis." | 7.69 | The effect of large-dose prednisone therapy on IgG subclasses in multiple sclerosis. ( Losy, J; Michałowska-Wender, G; Wender, M, 1994) |
| "The author presents evidence from published papers of research done by numerous investigators that Multiple Sclerosis (MS) is an autoimmune disease, that the target tissue is the myelin sheath which covers the nerve fibers in the brain and spinal cord, that Myelin Basic Protein (MBP) is the antigen or one of the antigens involved, that the autoimmune reaction is effected by sensitized lymphocytes together with a specific antibody, that Experimental Allergic Encephalomyelitis (EAE) produced in animals can be used as a model for MS, and that the autoimmune reaction in MS can possibly be suppressed by the use of MBP given by an intravenous procedure together with an immunosuppressive drug and a corticosteroid." | 7.67 | Suppression of the immune reaction in multiple sclerosis might be achieved by intravenous injections of myelin basic protein, concomitant with the administration of an immunosuppressant and a corticosteroid. ( Eidinoff, H, 1988) |
| "The author presents evidence from published papers of research done by numerous investigators that Multiple, Sclerosis (MS) is an autoimmune disease, that the target tissue is the myelin sheath which covers the nerve fibers in the brain and spinal cord, that Myelin Basic Protein (MBP) is the antigen or one of the antigens involved, that the autoimmune reaction is effected by sensitized lymphocytes together with a specific antibody, that Experimental Allergic Encephalomyelitis (EAE) produced in animals can be used as a model for MS, and that the autoimmune reaction in MS can possibly be suppressed by the use of MBP given by an intravenous procedure together with an immunosuppressive drug and a corticosteroid." | 7.67 | Suppression of the immune reaction in multiple sclerosis might be achieved by intravenous injections of myelin basic protein, concomitant with the administration of an immunosuppressant and a corticosteroid. ( Eidinoff, H, 1988) |
| "CSF levels of myelin basic protein (MBP) and intrathecally produced CSF IgG (de novo IgG) were measured in 11 chronic progressive multiple sclerosis patients with a deteriorating course of the disease for at least 6 months preceding observation and a reference group of 17 neurological patients suffering from disc herniation." | 7.67 | The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. ( Doesburg, W; Hommes, OR; Lamers, KJ; Uitdehaag, BM; von Geel, WJ; Wevers, RA, 1988) |
| "In 30 patients with multiple sclerosis treated with prednisone the morphological status of the gastric mucosa was assessed endoscopically and microscopically, and the secretory function of the stomach was studied determining hydrophloric acid, sialic acid and total glycoproteins in gastric juice before and after 6 weeks of prednisone treatment." | 7.67 | [Morphological and functional condition of the stomach in multiple sclerosis patients treated with prednisone]. ( Chmielewski, H; Chojnacki, J; Klupińska, G, 1989) |
| "Intra-blood-brain-barrier IgG synthesis rates and oligoclonal IgG banding patterns were examined in 9 patients with multiple sclerosis who were treated with azathioprine and steroids for 2 to 4." | 7.67 | Azathioprine and steroids are not more effective in decreasing multiple sclerosis intra-blood-brain-barrier IgG synthesis than steroids alone. ( Ellison, GW; Lee, M; Myers, LW; Shapshak, P; Staugaitis, SM; Tourtellotte, WW, 1985) |
| "32 patients with the chronic progressive form of the multiple sclerosis were treated with high doses of cyclophosphamide and prednisone during 20 days, to produce immunosuppression." | 7.65 | Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. ( Hommes, OR; Lamers, KJ; Prick, JJ, 1975) |
| "Azathioprine only was given during the three following year." | 6.66 | [Treatment of progressive and severe forms of multiple sclerosis using a combination of antilymphocyte serum, azathioprine and prednisone. Clinical and biological results. Comparison with a control group treated with azathioprine and prednisone only. 4-ye ( de Saxcé, H; Lhermitte, F; Marteau, R, 1987) |
| "In the original 2-year ASA study, 181 patients with early relapsing-remitting multiple sclerosis were randomised into 3 treatment arms: those treated with interferon beta (n=60), with interferon beta and low-dose azathioprine (n=58), and interferon beta, azathioprine and low-dose prednisone (n=63)." | 5.16 | Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. ( Dolezal, O; Havrdova, E; Horakova, D; Kalincik, T; Krasensky, J; Seidl, Z; Vaneckova, M, 2012) |
| "To determine whether low-dose prednisone reduces flu-like symptoms at the initiation of interferon beta 1-b (IFNbeta-1b), we studied 71 patients with clinically definite, relapsing-remitting multiple sclerosis who were started on IFNbeta-1b." | 5.08 | Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS. ( Marzo, ME; Montalban, X; Nos, C; Río, J; Tintoré, M, 1998) |
| "We have monitored the cell surface phenotypic changes occurring in T, B and NK cells of chronic progressive multiple sclerosis (MS) patients after total lymphoid irradiation (TLI) plus low-dose prednisone (TLI-LDP) therapy in comparison to sham TLI-LDP." | 5.08 | The effect of total lymphoid irradiation and low-dose steroids on T lymphocyte populations in multiple sclerosis: correlation with clinical and MRI status. ( Bansil, S; Cook, SD; Denny, T; Devereux, C; Dowling, P; Jotkowitz, A; Molinaro, D; Oleske, J; Rohowsky-Kochan, C; Troiano, R; Wolansky, L; Zito, G, 1997) |
| " Recurrences were more frequent in patients with multiple sclerosis and in those treated with oral prednisone alone." | 5.08 | Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group. ( , 1997) |
| "In a double-blind prospective randomized trial, we assessed the efficacy and safety of modified total lymphoid irradiation (TLI) plus low dose prednisone (TLI-LDP) as compared to sham TLI plus identical prednisone therapy (sham TLI-LDP) in 46 patients with progressive forms of multiple sclerosis (MS)." | 5.08 | Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis. ( Bansil, S; Boos, J; Cook, SD; Devereux, C; Dowling, P; Goldstein, J; Guarnaccia, J; Haffty, B; Jotkowitz, A; Rohowsky-Kochan, C; Sheffet, A; Troiano, R; Volmer, T; Wolansky, L; Zito, G, 1997) |
| "Intravenous methylprednisolone followed by oral prednisone speeds the recovery of visual loss due to optic neuritis and results in slightly better vision at six months." | 5.07 | A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. ( Anderson, MM; Beck, RW; Buckley, EG; Cleary, PA; Corbett, JJ; Kaufman, DI; Keltner, JL; Kupersmith, MJ; Miller, NR; Shults, WT, 1992) |
| "The effects of acute pharmacologic steroid treatment on skeletal and mineral metabolism were assessed in 56 multiple sclerosis patients who were to receive 1 g intravenous methylprednisolone for 10 days, followed by a 4 day intravenous and 28 day oral glucocorticoid taper." | 5.07 | High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. ( Cosman, F; Herbert, J; Lindsay, R; Nieves, J; Shen, V, 1994) |
| "We conducted a multicenter study in which 389 patients with acute optic neuritis (and without known multiple sclerosis) were randomly assigned to receive intravenous methylprednisolone (250 mg every six hours) for 3 days followed by oral prednisone (1 mg per kilogram of body weight) for 11 days, oral prednisone (1 mg per kilogram) alone for 14 days, or placebo for 14 days." | 5.07 | The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. ( Beck, RW; Brown, CH; Cleary, PA; Kaufman, DI; Kupersmith, MJ; Paty, DW; Trobe, JD, 1993) |
| "Isoprinosine, a drug enhancing the cellular immunity, was administered to 11 patients with multiple sclerosis (MS) for a period of 60 days." | 5.05 | Isoprinosine in multiple sclerosis treatment: a preliminary study. ( Delodovici, M; Mazzarello, P; Pinelli, P; Poloni, M; Rocchelli, B, 1982) |
| "A 38-year-old woman on treatment with dimethyl fumarate for multiple sclerosis presented with a 7-day history of weakness and fatigue." | 3.91 | The first reported case of drug-induced hemolytic anemia caused by dimethyl fumarate in a patient with multiple sclerosis. ( Carcelén-Gadea, M; Castro-Izaguirre, E; Marín, M; Quintanilla-Bordás, C, 2019) |
| " Numerous clinical interventions, including those used to treat multiple sclerosis (MS), have confirmed prednisone (PDN) as a powerful anti-inflammatory drug that reduces the inflammatory response and promotes tissue repair in multiple inflammation sites." | 3.88 | Prednisone alleviates demyelination through regulation of the NLRP3 inflammasome in a C57BL/6 mouse model of cuprizone-induced demyelination. ( Cao, T; Chen, N; Fan, H; Jiang, Z; Lu, G; Wu, M; Yao, R; Yu, H; Zhang, Y, 2018) |
| " The patient underwent therapy with prednisone and heparin but developed heparin-induced thrombocytopenia." | 3.77 | Hypereosinophilic syndrome with cardiac involvement in a pregnant patient with multiple sclerosis. ( Darki, A; Jacobs, W; Kodali, PP; McPheters, JP; Patel, MR; Virk, H, 2011) |
| "Prednisone and methylprednisolone are well absorbed orally and have lower treatment costs than IV methylprednisolone, but concern that low-dose corticosteroid may cause increased disease activity and that high oral doses may cause gastric ulceration inhibits use of oral therapy for MS attacks." | 3.70 | Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis. ( Enns, R; Hilsden, RJ; Meddings, JB; Metz, LM; Sabuda, D, 1999) |
| "The effect of large-dose prednisone therapy (3960 mg over 56 days) on IgG subclasses in the cerebrospinal fluid and sera, as well as on their intrathecal synthesis, was studied in 15 patients with clinically definite multiple sclerosis." | 3.69 | The effect of large-dose prednisone therapy on IgG subclasses in multiple sclerosis. ( Losy, J; Michałowska-Wender, G; Wender, M, 1994) |
| "We present a case of pemoline-induced autoimmune hepatitis in a 46-yr-old woman who received the drug for management of her multiple sclerosis." | 3.69 | Pemoline-induced autoimmune hepatitis. ( Grace, ND; Kane, M; Sterling, MJ, 1996) |
| "In a longitudinal prospective study, we followed 56 patients (17 men, 29 women) with definite multiple sclerosis (MS), who were treated with high-dose intravenous methylprednisolone (IVMP), 10 consecutive days with 1000 mg IVMP daily." | 3.69 | Follow-up study of MS patients treated with high-dose intravenous methylprednisolone. ( Barkhof, F; Borm, GF; Frequin, ST; Hommes, OR; Lamers, KJ, 1994) |
| "It is now well established that clinically stable patients with relapsing-remitting multiple sclerosis have ongoing disease activity when evaluated by serial gadolinium-enhanced (Gd-DTPA) magnetic resonance imaging (MRI) scans." | 3.68 | Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. ( Albert, PS; Armstrong, M; Frank, JA; Maloni, H; Martin, R; McFarland, HF; McFarlin, DE; Smith, ME; Stone, LA, 1993) |
| "CSF levels of myelin basic protein (MBP) and intrathecally produced CSF IgG (de novo IgG) were measured in 11 chronic progressive multiple sclerosis patients with a deteriorating course of the disease for at least 6 months preceding observation and a reference group of 17 neurological patients suffering from disc herniation." | 3.67 | The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. ( Doesburg, W; Hommes, OR; Lamers, KJ; Uitdehaag, BM; von Geel, WJ; Wevers, RA, 1988) |
| "Six consecutive patients with multiple sclerosis and lesions contrast enhancing on computed tomographic scan were treated with high-dose intravenous infusions of methylprednisolone." | 3.67 | Effect of high-dose intravenous steroid administration on contrast-enhancing computed tomographic scan lesions in multiple sclerosis. ( Cook, S; Dowling, P; Hafstein, M; Ruderman, M; Troiano, R, 1984) |
| "In 30 patients with multiple sclerosis treated with prednisone the morphological status of the gastric mucosa was assessed endoscopically and microscopically, and the secretory function of the stomach was studied determining hydrophloric acid, sialic acid and total glycoproteins in gastric juice before and after 6 weeks of prednisone treatment." | 3.67 | [Morphological and functional condition of the stomach in multiple sclerosis patients treated with prednisone]. ( Chmielewski, H; Chojnacki, J; Klupińska, G, 1989) |
| "In light of encouraging preliminary data, 45 patients with severely progressive multiple sclerosis underwent long-term plasmapheresis in conjunction with low-dose cyclophosphamide and prednisone therapy." | 3.67 | Plasmapheresis with immunosuppressive drug therapy in progressive multiple sclerosis. A pilot study. ( Khatri, BO; Koethe, SM; McQuillen, MP, 1984) |
| "Intra-blood-brain-barrier IgG synthesis rates and oligoclonal IgG banding patterns were examined in 9 patients with multiple sclerosis who were treated with azathioprine and steroids for 2 to 4." | 3.67 | Azathioprine and steroids are not more effective in decreasing multiple sclerosis intra-blood-brain-barrier IgG synthesis than steroids alone. ( Ellison, GW; Lee, M; Myers, LW; Shapshak, P; Staugaitis, SM; Tourtellotte, WW, 1985) |
| "The author presents evidence from published papers of research done by numerous investigators that Multiple, Sclerosis (MS) is an autoimmune disease, that the target tissue is the myelin sheath which covers the nerve fibers in the brain and spinal cord, that Myelin Basic Protein (MBP) is the antigen or one of the antigens involved, that the autoimmune reaction is effected by sensitized lymphocytes together with a specific antibody, that Experimental Allergic Encephalomyelitis (EAE) produced in animals can be used as a model for MS, and that the autoimmune reaction in MS can possibly be suppressed by the use of MBP given by an intravenous procedure together with an immunosuppressive drug and a corticosteroid." | 3.67 | Suppression of the immune reaction in multiple sclerosis might be achieved by intravenous injections of myelin basic protein, concomitant with the administration of an immunosuppressant and a corticosteroid. ( Eidinoff, H, 1988) |
| "Interviews on changes in the menstrual cycle were taken from 38 women of fertile age, several years after immunosuppressive treatment (IS) with prednisone and cyclophosphamide (CP) for definite multiple sclerosis (MS)." | 3.67 | Amenorrhea after immunosuppressive treatment of multiple sclerosis. ( Hommes, OR; Linssen, WH; Notermans, NC; Rolland, R, 1987) |
| "The author presents evidence from published papers of research done by numerous investigators that Multiple Sclerosis (MS) is an autoimmune disease, that the target tissue is the myelin sheath which covers the nerve fibers in the brain and spinal cord, that Myelin Basic Protein (MBP) is the antigen or one of the antigens involved, that the autoimmune reaction is effected by sensitized lymphocytes together with a specific antibody, that Experimental Allergic Encephalomyelitis (EAE) produced in animals can be used as a model for MS, and that the autoimmune reaction in MS can possibly be suppressed by the use of MBP given by an intravenous procedure together with an immunosuppressive drug and a corticosteroid." | 3.67 | Suppression of the immune reaction in multiple sclerosis might be achieved by intravenous injections of myelin basic protein, concomitant with the administration of an immunosuppressant and a corticosteroid. ( Eidinoff, H, 1988) |
| "In six of eight patients with chronic progressive multiple sclerosis (MS) who were previously unresponsive to corticosteroid medication, moderate but unequivocal improvement occurred after short-term plasmapheresis, prednisone, and azathioprine therapy." | 3.66 | Plasmapheresis in multiple sclerosis: preliminary study. ( Dawson, DM; Weiner, HL, 1980) |
| "In seven of eight patients with progressive multiple sclerosis subjected to long-term plasmapheresis in combination with azathioprine and pulsed prednisone therapy, we found modest improvement of neurologic function." | 3.66 | Plasmapheresis in multiple sclerosis: preliminary findings. ( Bornstein, MB; Dau, PC; Johnson, KP; Panitch, HS; Petajan, JH, 1980) |
| "Intravenous steroid followed by oral prednisone was administered to patients with Guillain-Barré syndrome (five), acute transverse myelitis (three), and multiple sclerosis in acute relapse (seven)." | 3.66 | Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis. ( Bosch, VV; Cook, SD; Dowling, PC, 1980) |
| "39 patients with chronic-progressive multiple sclerosis were treated with a short course of intensive immunosuppression in high doses of cyclophosphamide and prednisone." | 3.66 | Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. ( Hommers, OR; Lamers, KJ; Reekers, P, 1980) |
| "32 patients with the chronic progressive form of the multiple sclerosis were treated with high doses of cyclophosphamide and prednisone during 20 days, to produce immunosuppression." | 3.65 | Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. ( Hommes, OR; Lamers, KJ; Prick, JJ, 1975) |
| "Prednisone treatment during the first month on the drug prevented the interferon-gamma-secreting cell surge." | 2.68 | Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. ( Arnason, BG; Dayal, AS; Jensen, MA; Lledo, A, 1995) |
| "Azathioprine only was given during the three following year." | 2.66 | [Treatment of progressive and severe forms of multiple sclerosis using a combination of antilymphocyte serum, azathioprine and prednisone. Clinical and biological results. Comparison with a control group treated with azathioprine and prednisone only. 4-ye ( de Saxcé, H; Lhermitte, F; Marteau, R, 1987) |
| "In our patient, sarcoidosis developed after 3 years of continuous recombinant interferon-beta therapy, dosed 3 times a week." | 2.48 | Sarcoidosis triggered by interferon-Beta treatment of multiple sclerosis: a case report and focused literature review. ( Chakravarty, SD; Crow, MK; Harris, ME; Schreiner, AM, 2012) |
| "Acute isolated optic neuritis is often the first manifestation of multiple sclerosis (MS)." | 1.35 | [Management of isolated optic neuritis in France: survey of neurologists and ophthalmologists]. ( Atkins, EJ; Biousse, V; Calvetti, O; Drews-Botsch, CD; Newman, NJ; Vignal-Clermont, C, 2008) |
| "However, there are conditions in which syringomyelia is not associated with evident persistent CSF-flow obstruction, as in the case of inflammatory spinal cord lesions." | 1.34 | Pathogenetic role of myelitis for syringomyelia. ( Bergamaschi, R; Bogdanov, EI; Mikhaylov, IM; Moglia, A; Pichiecchio, A; Ravaglia, S, 2007) |
| "Susac's syndrome is a rare disorder characterized by the triad of microangiopathy of the brain and retina with hearing loss." | 1.31 | Susac's syndrome: beneficial effects of corticosteroid therapy in a Japanese case. ( Hashimoto, Y; Tashima, K; Uchino, M; Uyama, E; Yonehara, T, 2001) |
| "The diagnosis of optic neuritis is based on clinical signs and symptoms." | 1.29 | [Neuro-ophthalmology--new challenges]. ( Stankiewicz, A, 1995) |
| " The first patient suffered from ulcerative colitis and developed Guillain-Barré syndrome when the steroid dosage was being tapered." | 1.27 | Appearance of Guillain-Barré syndrome in patients during corticosteroid treatment. ( Abramsky, O; Steiner, I; Wirguin, I, 1986) |
| "In fact, multiple sclerosis was considered the most likely diagnosis in each of these patients before diagnosis of Sjögren's syndrome, and each patient met criteria for definite multiple sclerosis." | 1.27 | Primary Sjögren's syndrome with central nervous system disease mimicking multiple sclerosis. ( Alexander, EL; Alexander, GE; Jerdan, MS; Lejewski, JE; Malinow, K; Provost, TT, 1986) |
| "Carbamazepine was successful in arresting the hiccups in one of the cases presented." | 1.26 | Hoquet diabolique: intractable hiccups as a manifestation of multiple sclerosis. ( McFarling, DA; Susac, JO, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 100 (52.63) | 18.7374 |
| 1990's | 47 (24.74) | 18.2507 |
| 2000's | 27 (14.21) | 29.6817 |
| 2010's | 14 (7.37) | 24.3611 |
| 2020's | 2 (1.05) | 2.80 |
| Authors | Studies |
|---|---|
| Leckey, R | 1 |
| Borsellino, L | 1 |
| Rawlings, AM | 1 |
| Ashkenas, J | 1 |
| Suri, A | 1 |
| Zecca, C | 1 |
| Disanto, G | 1 |
| Riccitelli, GC | 1 |
| Candrian, U | 1 |
| Deandrea, M | 1 |
| Limone, PP | 1 |
| Sacco, R | 1 |
| Gobbi, C | 1 |
| Yu, H | 1 |
| Wu, M | 1 |
| Lu, G | 1 |
| Cao, T | 1 |
| Chen, N | 1 |
| Zhang, Y | 1 |
| Jiang, Z | 1 |
| Fan, H | 1 |
| Yao, R | 1 |
| García Ródenas, MDM | 1 |
| Gayá García-Manso, I | 1 |
| García Sevila, R | 1 |
| Quintanilla-Bordás, C | 1 |
| Castro-Izaguirre, E | 1 |
| Carcelén-Gadea, M | 1 |
| Marín, M | 1 |
| Taylor, MR | 1 |
| Gaco, D | 1 |
| Nakamura, K | 1 |
| Guizard, N | 1 |
| Fonov, VS | 1 |
| Narayanan, S | 1 |
| Collins, DL | 1 |
| Arnold, DL | 1 |
| Dhrami-Gavazi, E | 1 |
| Goldberg, NR | 1 |
| Freund, KB | 1 |
| Vora, RA | 1 |
| Williams, BJ | 1 |
| Skinner, HJ | 1 |
| Maria, BL | 1 |
| Volpe, NJ | 1 |
| Beck, RW | 8 |
| Gal, RL | 4 |
| Hoegerl, C | 1 |
| Zboray, S | 1 |
| Bonaci-Nikolic, B | 1 |
| Jeremic, I | 1 |
| Andrejevic, S | 1 |
| Sefik-Bukilica, M | 1 |
| Stojsavljevic, N | 1 |
| Drulovic, J | 1 |
| Cohen, M | 1 |
| Rocher, F | 1 |
| Brunschwig, C | 1 |
| Lebrun, C | 1 |
| Davis, M | 1 |
| Auh, S | 1 |
| Riva, M | 1 |
| Richert, ND | 1 |
| Frank, JA | 2 |
| McFarland, HF | 2 |
| Bagnato, F | 1 |
| Clark, D | 1 |
| Kebede, W | 1 |
| Eggenberger, E | 2 |
| Sheth, SS | 1 |
| Posner, MA | 1 |
| Querques, G | 1 |
| Bux, AV | 1 |
| Forte, R | 1 |
| Francesco, P | 1 |
| Cristiana, I | 1 |
| Noci, ND | 1 |
| Darki, A | 1 |
| Kodali, PP | 1 |
| McPheters, JP | 1 |
| Virk, H | 1 |
| Patel, MR | 1 |
| Jacobs, W | 1 |
| Alderazi, YJ | 1 |
| Coons, SW | 1 |
| Chapman, K | 1 |
| Kalincik, T | 1 |
| Horakova, D | 1 |
| Dolezal, O | 1 |
| Krasensky, J | 1 |
| Vaneckova, M | 1 |
| Seidl, Z | 1 |
| Havrdova, E | 1 |
| Chakravarty, SD | 1 |
| Harris, ME | 1 |
| Schreiner, AM | 1 |
| Crow, MK | 1 |
| Liu, XY | 1 |
| Sun, Y | 1 |
| Benz, MS | 1 |
| Glaser, JS | 2 |
| Davis, JL | 1 |
| Trobe, JD | 4 |
| Moke, PS | 3 |
| Xing, D | 1 |
| Bhatti, MT | 1 |
| Brodsky, MC | 1 |
| Buckley, EG | 2 |
| Chrousos, GA | 1 |
| Corbett, J | 2 |
| Goodwin, JA | 1 |
| Katz, B | 2 |
| Kaufman, DI | 3 |
| Keltner, JL | 2 |
| Kupersmith, MJ | 5 |
| Miller, NR | 2 |
| Nazarian, S | 1 |
| Orengo-Nania, S | 1 |
| Savino, PJ | 1 |
| Shults, WT | 2 |
| Smith, CH | 1 |
| Wall, M | 1 |
| CLAISSE, R | 2 |
| SUQUET, Y | 1 |
| ANDREOLI, G | 2 |
| HARTMANN, L | 1 |
| WALCHER, W | 1 |
| CURCIO, FI | 1 |
| SCORNIK, JS | 1 |
| TIVERON, HS | 1 |
| ALBANESE, AA | 1 |
| LORENZE, EJ | 1 |
| ORTO, LA | 1 |
| SMULLYAN, I | 1 |
| FROWEIN, R | 1 |
| DORNDORF, W | 1 |
| BLUMENSCHEIN, F | 1 |
| KIBLER, RF | 1 |
| Morrow, SA | 1 |
| Stoian, CA | 1 |
| Dmitrovic, J | 1 |
| Chan, SC | 1 |
| Metz, LM | 2 |
| Yoshida, EM | 1 |
| Devonshire, VA | 1 |
| Prout, AJ | 1 |
| Strupp, M | 1 |
| Frank, RD | 1 |
| Altenwerth, B | 1 |
| Brandenburg, VM | 1 |
| Nolden-Koch, M | 1 |
| Block, F | 1 |
| van Rensburg, SJ | 1 |
| Kotze, MJ | 1 |
| Hon, D | 1 |
| Haug, P | 1 |
| Kuyler, J | 1 |
| Hendricks, M | 1 |
| Botha, J | 1 |
| Potocnik, FC | 1 |
| Matsha, T | 1 |
| Erasmus, RT | 1 |
| Braun Hashemi, CA | 1 |
| Zang, YC | 1 |
| Arbona, JA | 1 |
| Bauerle, JA | 1 |
| Frazer, ML | 1 |
| Lee, H | 1 |
| Flury, L | 1 |
| Moore, ES | 1 |
| Kolar, MC | 1 |
| Washington, RY | 1 |
| Kolar, OJ | 2 |
| Ravaglia, S | 1 |
| Bogdanov, EI | 1 |
| Pichiecchio, A | 1 |
| Bergamaschi, R | 1 |
| Moglia, A | 1 |
| Mikhaylov, IM | 1 |
| Calvetti, O | 1 |
| Vignal-Clermont, C | 1 |
| Drews-Botsch, CD | 1 |
| Atkins, EJ | 1 |
| Newman, NJ | 1 |
| Biousse, V | 1 |
| Rowell, NR | 1 |
| Waigt, A | 1 |
| Górny, MK | 2 |
| Hommers, OR | 1 |
| Lamers, KJ | 5 |
| Reekers, P | 1 |
| Shih, WW | 1 |
| Ellison, GW | 2 |
| Myers, LW | 2 |
| Durkos-Smith, D | 1 |
| Fahey, JL | 1 |
| Neighbour, PA | 1 |
| Grayzel, AI | 1 |
| Miller, AE | 1 |
| Hauser, SL | 2 |
| Fosburg, M | 1 |
| Kevy, S | 1 |
| Weiner, HL | 2 |
| Mazzarello, P | 1 |
| Rocchelli, B | 1 |
| Poloni, M | 1 |
| Delodovici, M | 1 |
| Pinelli, P | 1 |
| Seil, FJ | 1 |
| Westall, FC | 1 |
| Romine, JS | 1 |
| Salk, J | 1 |
| Patzold, U | 1 |
| Wurster, U | 1 |
| Mardt, K | 1 |
| Schiemann, M | 1 |
| Khatri, BO | 1 |
| Koethe, SM | 1 |
| McQuillen, MP | 1 |
| Dowling, PC | 4 |
| Bosch, VV | 1 |
| Cook, SD | 7 |
| Tourtellotte, WW | 4 |
| Baumhefner, RW | 2 |
| Potvin, AR | 2 |
| Ma, BI | 2 |
| Potvin, JH | 2 |
| Mendez, M | 1 |
| Syndulko, K | 2 |
| Petrovich, Z | 1 |
| Snyder, BD | 1 |
| Lakatua, DJ | 1 |
| Doe, RP | 1 |
| Dau, PC | 2 |
| Petajan, JH | 1 |
| Johnson, KP | 2 |
| Panitch, HS | 1 |
| Bornstein, MB | 1 |
| Safkan, B | 1 |
| Knuuttila, M | 1 |
| Hommes, OR | 7 |
| van Geel, W | 1 |
| Wajgt, A | 3 |
| Jenek, R | 1 |
| Troiano, R | 6 |
| Hafstein, M | 1 |
| Ruderman, M | 1 |
| Dowling, P | 3 |
| Cook, S | 1 |
| Peselow, ED | 1 |
| Fieve, RR | 1 |
| Deutsch, SI | 1 |
| Kaufman, M | 1 |
| Aerts, F | 1 |
| Bahr, U | 1 |
| Schulten, HR | 1 |
| Aita, JF | 2 |
| Dawson, DM | 1 |
| Alaev, BA | 1 |
| Müller, J | 2 |
| Sauermann, W | 2 |
| Kreiner, R | 1 |
| Bhoopal, V | 1 |
| Brueschke, EE | 1 |
| Owen, RL | 1 |
| Spitler, LE | 1 |
| Kappos, L | 1 |
| Núñez, M | 1 |
| Miralles, ES | 1 |
| Muñoz, E | 1 |
| Ledo, A | 1 |
| Stankiewicz, A | 1 |
| Whitaker, JN | 1 |
| Layton, BA | 1 |
| Herman, PK | 1 |
| Kachelhofer, RD | 1 |
| Burgard, S | 1 |
| Bartolucci, AA | 1 |
| Devereux, C | 4 |
| Bansil, S | 4 |
| Zito, G | 5 |
| Sheffet, A | 2 |
| Jotkowitz, A | 3 |
| Rohowsky-Kochan, C | 5 |
| Frequin, ST | 1 |
| Barkhof, F | 1 |
| Borm, GF | 1 |
| Cosman, F | 1 |
| Nieves, J | 1 |
| Herbert, J | 1 |
| Shen, V | 1 |
| Lindsay, R | 1 |
| Corbett, JJ | 2 |
| Olek, MJ | 1 |
| Khan, OA | 2 |
| Losy, J | 1 |
| Michałowska-Wender, G | 1 |
| Wender, M | 2 |
| Cleary, PA | 3 |
| Paty, DW | 2 |
| Brown, CH | 1 |
| Silberberg, DH | 1 |
| Glabiński, A | 1 |
| Tawsek, NS | 1 |
| Bartosz, G | 1 |
| Kaufman, D | 1 |
| Ebers, G | 2 |
| McFarland, H | 1 |
| Johnson, K | 1 |
| Reingold, S | 1 |
| Whitaker, J | 1 |
| Noseworthy, JH | 3 |
| Ebers, GC | 2 |
| Vandervoort, MK | 3 |
| Farquhar, RE | 2 |
| Yetisir, E | 3 |
| Roberts, R | 3 |
| Shetty, T | 1 |
| Smith, ME | 1 |
| Stone, LA | 1 |
| Albert, PS | 1 |
| Martin, R | 1 |
| Armstrong, M | 1 |
| Maloni, H | 1 |
| McFarlin, DE | 1 |
| Masdeu, JC | 1 |
| Dayal, AS | 1 |
| Jensen, MA | 1 |
| Lledo, A | 1 |
| Arnason, BG | 1 |
| Sterling, MJ | 1 |
| Kane, M | 1 |
| Grace, ND | 1 |
| Gelati, M | 1 |
| Lamperti, E | 1 |
| Dufour, A | 1 |
| Corsini, E | 1 |
| Venegoni, E | 1 |
| Milanese, C | 1 |
| Nespolo, A | 1 |
| Salmaggi, A | 1 |
| Wolansky, L | 2 |
| Guarnaccia, J | 1 |
| Haffty, B | 1 |
| Goldstein, J | 1 |
| Boos, J | 1 |
| Volmer, T | 1 |
| Molinaro, D | 1 |
| Denny, T | 1 |
| Oleske, J | 1 |
| Río, J | 3 |
| Nos, C | 1 |
| Marzo, ME | 1 |
| Tintoré, M | 2 |
| Montalban, X | 3 |
| Erneston, AG | 1 |
| Hebel, JR | 1 |
| Martínez-Cáceres, EM | 1 |
| Barrau, M | 1 |
| Durán, I | 1 |
| Borrás, C | 1 |
| Sabuda, D | 1 |
| Hilsden, RJ | 1 |
| Enns, R | 1 |
| Meddings, JB | 1 |
| Lakatos, P | 1 |
| Nagy, Z | 1 |
| Kiss, L | 1 |
| Horvath, C | 1 |
| Takacs, I | 1 |
| Foldes, J | 1 |
| Speer, G | 1 |
| Bossanyi, A | 1 |
| Oksenberg, JR | 1 |
| Lincoln, R | 1 |
| Garovoy, J | 1 |
| Cole, SR | 1 |
| Kip, KE | 2 |
| Long, DT | 2 |
| Leiba, H | 1 |
| Schatz, NJ | 1 |
| Siatkowski, RM | 1 |
| Tashima, K | 1 |
| Uyama, E | 1 |
| Hashimoto, Y | 1 |
| Yonehara, T | 1 |
| Uchino, M | 1 |
| Kiefer, G | 1 |
| Rieckmann, P | 1 |
| Blair, RC | 1 |
| Katz, BJ | 1 |
| Murthy, K | 1 |
| Brandes, D | 1 |
| Sajben, N | 1 |
| Ma, B | 1 |
| Comiso, P | 1 |
| Potvin, A | 1 |
| Costanza, A | 1 |
| Korelitz, J | 1 |
| McFarling, DA | 1 |
| Susac, JO | 1 |
| Sears, ES | 1 |
| Tindall, RS | 1 |
| Zarnow, H | 1 |
| Fischer, W | 1 |
| Frey, H | 1 |
| Molnár, G | 1 |
| Knight, SC | 2 |
| Abbosh, J | 3 |
| Lance, EM | 3 |
| Prick, JJ | 1 |
| Munro, A | 1 |
| O'Brien, J | 1 |
| Kremer, M | 1 |
| Jones, VE | 1 |
| Knight, S | 1 |
| Medawar, PB | 1 |
| Oliveira, TV | 1 |
| Gorz-Reinhardt, AM | 1 |
| Gracia, CM | 1 |
| Bittencourt, PR | 1 |
| Gentiloni, N | 1 |
| Schiavino, D | 1 |
| Della Corte, F | 1 |
| Ricci, E | 1 |
| Colosimo, C | 1 |
| Toshniwal, PK | 1 |
| Zarling, EJ | 1 |
| Colucciello, M | 1 |
| Brucker, AJ | 1 |
| Goyal, A | 1 |
| Scholl, GB | 1 |
| Song, HS | 1 |
| Wray, SH | 1 |
| Penman, M | 1 |
| Shumak, K | 1 |
| Seland, TP | 1 |
| Gent, M | 1 |
| Taylor, DW | 1 |
| Anderson, MM | 1 |
| Polman, CH | 1 |
| van der Wiel, HE | 1 |
| Miró, J | 1 |
| Amado, JA | 1 |
| Pesquera, C | 1 |
| López-Cordovilla, JJ | 1 |
| Berciano, J | 1 |
| Trozak, DJ | 1 |
| Todt, H | 1 |
| Eidinoff, H | 2 |
| Warren, KG | 2 |
| Catz, I | 1 |
| Carroll, DJ | 2 |
| Uitdehaag, BM | 1 |
| Doesburg, W | 1 |
| Wevers, RA | 1 |
| von Geel, WJ | 1 |
| Górny, M | 1 |
| Szczechowski, L | 1 |
| Grzybowski, G | 1 |
| Ochudło, S | 2 |
| Chmielewski, H | 1 |
| Chojnacki, J | 1 |
| Klupińska, G | 1 |
| Goodkin, DE | 1 |
| Plencner, S | 1 |
| Palmer-Saxerud, J | 1 |
| Teetzen, M | 1 |
| Hertsgaard, D | 1 |
| Jedlicka, P | 1 |
| Minden, SL | 1 |
| Orav, J | 1 |
| Schildkraut, JJ | 1 |
| Nath, A | 1 |
| Wolinsky, JS | 1 |
| Kerman, RH | 1 |
| Mayer, M | 1 |
| Staugaitis, SM | 1 |
| Shapshak, P | 1 |
| Lee, M | 1 |
| Hammann, KP | 1 |
| Röder, R | 1 |
| Gies, H | 1 |
| Hopf, HC | 1 |
| Hughes, RA | 1 |
| Tokarz, E | 1 |
| Michalowska, G | 1 |
| Steiner, I | 1 |
| Wirguin, I | 1 |
| Abramsky, O | 2 |
| Riley, D | 1 |
| Lang, AE | 1 |
| Gola, A | 1 |
| Niewolna, M | 1 |
| Weryńska, B | 1 |
| Linssen, WH | 1 |
| Notermans, NC | 1 |
| Rolland, R | 1 |
| Lhermitte, F | 1 |
| Marteau, R | 1 |
| de Saxcé, H | 1 |
| Bixenman, WW | 1 |
| Buchsbaum, HW | 1 |
| Durelli, L | 1 |
| Cocito, D | 1 |
| Riccio, A | 1 |
| Barile, C | 1 |
| Bergamasco, B | 1 |
| Baggio, GF | 1 |
| Perla, F | 1 |
| Delsedime, M | 1 |
| Gusmaroli, G | 1 |
| Bergamini, L | 1 |
| Gordon, PA | 1 |
| Etches, WS | 1 |
| Jeffrey, V | 1 |
| Marsh, L | 1 |
| Morrice, BL | 1 |
| Olmstead, D | 1 |
| Alexander, EL | 1 |
| Malinow, K | 1 |
| Lejewski, JE | 1 |
| Jerdan, MS | 1 |
| Provost, TT | 1 |
| Alexander, GE | 1 |
| Troiano, RA | 1 |
| Hafstein, MP | 1 |
| Ruderman, MI | 1 |
| Rauch, HC | 1 |
| Montgomery, IN | 1 |
| Kaplan, J | 1 |
| Snyder, DH | 1 |
| Reichl, W | 1 |
| Webb, C | 1 |
| Teitelbaum, D | 1 |
| Arnon, R | 1 |
| Sela, M | 1 |
| Magierowski, S | 1 |
| Cendrowski, W | 2 |
| Cancilla, PA | 1 |
| Andrews, JM | 1 |
| Rose, AS | 1 |
| Landy, PJ | 1 |
| Ohlrich, GD | 1 |
| Poppe, W | 1 |
| Schwenkbier, H | 1 |
| Wieczorek, V | 2 |
| Darnell, D | 1 |
| Abrams, BM | 1 |
| Moroney, J | 1 |
| Sigwald, J | 1 |
| Mazalton, A | 1 |
| Raymondeaud, C | 1 |
| Piot, C | 1 |
| Jacquillat, C | 1 |
| Riekkinen, PJ | 1 |
| Rinne, UK | 1 |
| Feudell, P | 1 |
| Eisen, AA | 1 |
| Norris, JW | 1 |
| Kaplicki, M | 1 |
| Kozlowska, I | 1 |
| Weiss, B | 1 |
| Hackett, ER | 1 |
| Martinez, RD | 1 |
| Larson, PF | 1 |
| Paddison, RM | 1 |
| Gewurz, H | 2 |
| Moberg, A | 2 |
| Simmons, R | 1 |
| Pollara, B | 1 |
| Soll, R | 1 |
| Najarian, S | 1 |
| Pickering, RJ | 1 |
| Simmons, RL | 1 |
| Good, RA | 1 |
| Najarian, JS | 1 |
| Briggs, RC | 1 |
| Van den Noort, S | 2 |
| Stjernholm, RL | 2 |
| Burns, CP | 1 |
| Armentrout, SA | 1 |
| Gross, S | 1 |
| Lehnert, W | 1 |
| Brodkorb, W | 1 |
| Mikulska, E | 1 |
| de Fine Olivarius, AB | 1 |
| Thage, O | 1 |
| Fog, T | 1 |
| Giles, CL | 1 |
| Schunk, W | 1 |
| Gutmann, L | 1 |
| Thompson, HG | 1 |
| Martin, JD | 1 |
| Bartko, D | 2 |
| Böhmová, L | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)[NCT02258217] | 30 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| [NCT00000147] | 0 participants | Interventional | 1988-07-31 | Active, not recruiting | |||
| [NCT00000146] | Phase 3 | 0 participants | Interventional | 1988-07-31 | Active, not recruiting | ||
| Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis[NCT01337986] | Phase 2/Phase 3 | 53 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms From Pegylated Interferon Beta-1a[NCT03424733] | Phase 4 | 50 participants (Anticipated) | Interventional | 2017-09-25 | Recruiting | ||
| Observational Prospective Multicentered Study Evaluating Initial Clinical Presentation of Inflammatory Optic Neuritis (ON) Associated or Not With Autoantibodies Anti- Myelin-oligodendrocyte-glycoprotein (MOG-Ab)[NCT03345537] | 103 participants (Actual) | Observational | 2018-02-12 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Patients completed the ARMS survey after treatment for the new relapse.The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~The TCS score was calculated only for the time point after treatment of relapse. It was a sum of questions 4 (symptom improvement), 5 (ADL), and 6 (return to previous state of health (RSH)) were evaluated. Scores range from 0 to 30 units, with higher scores representing greater improvement/better functioning." (NCT02258217)
Timeframe: Follow-up visit
| Intervention | score on a scale (Mean) |
|---|---|
| Single Arm | 14.3 |
"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, history of patients from the survey after treatment for the new relapse will be collected.~The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~ADL scores were calculated from Part 1 (new relapse), question 3 and Part 2 (after treatment of relapse), question 5 both specifically refer to ADL;~Scale: ADL (Activities of Daily Living) Minimum value: 0 Maximum value: 9 Higher scores indicated better functioning/ improvement." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| ADL (new relapse) | ADL (after treatment of relapse) | |
| Single Arm | 3.1 | 4.9 |
"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, patients completed the survey after treatment for the new relapse.~The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~PCS was computed based on the sum of the ADL and RSH questions. The PCS was computed separately for Part 1 (new relapse) and Part 2 (after relapse treatment) and summarized descriptively; Higher scores indicating better functioning/greater improvement. The PCS scores were on a scale of 0 to 20 units." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| PCS (New relapse) | PCS (after treatment of relapse) | |
| Single Arm | 7.7 | 9.2 |
"Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, patients completed the survey after treatment for the new relapse. The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, and response to past treatment for MS relapses. Part two consists of 7 questions to evaluate treatment response in terms of relief from symptoms, functioning and tolerability.~Part 1 (new relapse) & Part 2 (after treatment of new relapse), question 6 were used to calculate RSH;~Scale: RSH (Return to previous health) Minimum value: -1 Maximum value: 10 Higher scores indicating a more complete return to previous state of health." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| RSH (new relapse) | RSH (after treatment of new relapse) | |
| Single Arm | 4.6 | 4.4 |
"This scaling score is obtained by performing a neurologic exam with specific attention to eight different neurologic functional systems: visual, pyramidal, cerebellar, bowel and bladder, cerebral, brainstem, sensory and other (10). The score is rated from zero (normal neurologic examination) to ten (death due to MS). This is the standard neurologic disability scale used in clinical trials for the evaluation of disability in patients with MS.~These scores were compared between pre and post phase using paired t-tests." (NCT02258217)
Timeframe: baseline and at follow-up
| Intervention | score on a scale (Median) | |
|---|---|---|
| EDSS score (new relapse) | EDSS score (after treatment of new relapse) | |
| Single Arm | 3.5 | 3.0 |
"Patients who reported a history of poor corticosteroid tolerability will be placed on Acthar and GASE scale will be given to assess tolerability to Acthar.~We listed the number of times a symptom was reported and was attributable to the ACTHAR treatment" (NCT02258217)
Timeframe: 1 week
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Headache | Dry Mouth | Dizziness | Tachycardia, palpitation or arrhythmia | Breathing problems | Abdominal pain | Nausea | Diarrhea | Reduced Appetite | Increased appetite | Difficulties with urination | Skin rash or itching | Tendency to develop bruises | Sweating | Hot flashes | Fatigue, loss of energy | Insomnia, sleeping problems | Nightmares or abnormal dreams | Back pain | Agitation | Irritability | Depressed Mood | Anxiety, fearfulness | Further symptoms | |
| Single Arm | 3 | 1 | 2 | 1 | 1 | 4 | 4 | 4 | 1 | 4 | 2 | 1 | 1 | 1 | 1 | 2 | 8 | 2 | 1 | 6 | 6 | 3 | 1 | 8 |
"The MSIS-29 is a self-reported questionnaire in which MS patients answer a series of 29 questions designed to capture the impact of multiple sclerosis on their life over the past 2 weeks (11). Twenty of the 29 questions assess the physical impact of MS and 9 questions assess the psychological impact of MS.~The psychological impact of MS was compared between pre and post phase using paired t-tests.~The psychological impact of MS was compared between pre and post phase using paired t-tests.~The score was on a scale of 9 to 45 points for MSIS psychological score.~Higher score indicate worse outcome." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| MSIS psychological(new relapse) | MSIS psychological(after treatment of new relapse) | |
| Single Arm | 29.4 | 26.3 |
"The MSIS-29 is a self-reported questionnaire in which MS patients answer a series of 29 questions designed to capture the impact of multiple sclerosis on their life over the past 2 weeks (11). Twenty of the 29 questions assess the physical impact of MS.~The physical impact of MS was compared between pre and post phase using paired t-tests. Each question is answered with points ranging from 1 to 5. Higher score indicates worse outcome. The total MSIS physical score ranges from 20 to 100 points with lower points indicating better impact." (NCT02258217)
Timeframe: baseline visit & follow-up after treatment
| Intervention | score on a scale (Median) | |
|---|---|---|
| MSIS physical (new relapse) | MSIS physical (after treatment of new relapse) | |
| Single Arm | 58.5 | 56 |
"The Self-Administered Gerocognitive Exam (SAGE) is designed to detect early signs of cognitive, memory or thinking impairments. It evaluates your thinking abilities and helps physicians to know how well your brain is working.~It consists of 12 questions which are scored at different scales. The final SAGE score is calculated as a sum of these 12 questions and it ranges from 0 to 22.~Higher score indicates better outcome." (NCT02258217)
Timeframe: baseline and follow-up
| Intervention | score on a scale (Median) | |
|---|---|---|
| SAGE (new relapse) | SAGE (after treatment of new relapse) | |
| Single Arm | 21 | 21 |
Intent to treat analysis of treatment effect in primary endpoint EDTRS 5% Contrast Sensitivity. Change in the number of letters able to read while on Dalfampridine and Placebo relative to their baseline scores. (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | letters (Mean) |
|---|---|
| Dalfampridine | 3 |
| Placebo | 2.5 |
Dalfampridine will change color vision Total Error Scores from baseline on the Farnsworth Munsell 100 Hue Sort Test. Farnsworth Munsell 100 Hue Test requires placing 100 color palettes in the correct order based upon color hue. Scores are determined by the frequency and severity of any displacement in the correct order. One error equates to one misplaced hue, by one step or position. An error score greater than 500 indicates virtually no color discrimination. An error score of 0 indicates no errors in ordering the hues. A Total Error Score of 0 to 128 could be seen in a normal population. (NCT01337986)
Timeframe: Visit 1 (Week 0 - baseline), Visit 2 (Week 3 - postintervention 1) and Visit 3 (Week 8 - post intervention 2)
| Intervention | FM100 Total Error Score (Mean) |
|---|---|
| Dalfampridine | -13.0 |
| Placebo | -10.6 |
Dalfampridine treatment will result in change in quality of life. The National Eye Institute Visual Function Questionnaire consists of 25 questions characterizing visual function at home and in the community. Score ranges from 100 (best) to 0 (worst). (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | NEI VFQ percentage (Median) |
|---|---|
| Dalfampridine | 0 |
| Placebo | 0 |
Intent to treat analysis of treatment effect in primary endpoint EDTRS 5% Contrast Sensitivity. Improvement from baseline scores. (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | 5% Contrast LogMAR Score (Mean) |
|---|---|
| Dalfampridine | 0.06 |
| Placebo | 0.05 |
Difference in Pelli- Robson Score at Visits 2 and 3 Relative to Visit 1 on Dalfampridine vs Placebo. Pelli-Robson is scored based upon the numbers read on the chart converted to LogMAR units. The scale is 0.00 (worst) to 2.35 (best). (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | units on a scale (Mean) |
|---|---|
| Dalfampridine | 0.07 |
| Placebo | 0.06 |
Per Protocol Analysis to assess difference in number of letters on the EDTRS 5% Contrast Sensitivity (LogMAR) Chart scores at visits 2 and 3 Relative to Visit 1 (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | letters (Mean) |
|---|---|
| Group B: Dalfampridine | 2 |
| Group B: Placebo | 2 |
| Group A: Placebo | 4 |
| Group A: Dalfampridine | 3 |
Per Protocol Analysis to assess differences in EDTRS 5% Contrast Sensitivity (LogMAR) Scores at visits 2 and 3 Relative to Visit 1 on patients taking Dalfampridine vs Placebo. (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | LogMAR Score (Mean) |
|---|---|
| Group B: Dalfampridine | -0.04 |
| Group B: Placebo | -0.06 |
| Group A: Placebo | -0.08 |
| Group A: Dalfampridine | -0.06 |
(NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | Percentages of eyes that improved (Number) |
|---|---|
| Dalfampridine | 9.7 |
| Placebo | 11.1 |
| Both | 11.1 |
| None | 68.1 |
Percentage of eyes that improved by one-line (5 letters) on the 5% contrast sensitivity chart (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | Percent of Eyes (Number) |
|---|---|
| Dalfampridine | 11.1 |
| Placebo | 15.3 |
| Both | 37.5 |
| Neither | 36.1 |
Visual evoked potential 60min P100 latency on dalfampridine vs. placebo. (NCT01337986)
Timeframe: Visit 1 (Week 0), Visit 2 (Week 3) and Visit 3 (Week 8)
| Intervention | milliseconds (Mean) |
|---|---|
| Dalfampridine | 121.6 |
| Placebo | 120.2 |
"The Visual Field Index (VFI) is a global index that assigns a number between 1% to 100% based on an aggregate percentage of visual function, with 100% being a perfect age-adjusted visual field.~Probability of falling in the best quartile for visual field (VFI) measures (Q1), relative to the three next quartiles for worse VFIs (Q2-4), while on Dalfampridine vs Placebo. Due to the clustered observations at different times in a cross-over design, the visual field data is not suited to a normal theory model and should not be expressed as a continuous variable. Thus, a categorical model that uses a multinomial distribution for measurement of 4 categories was selected for proper statistical modeling, with results expressed as odds ratios." (NCT01337986)
Timeframe: Visit 1 (Week 0 - baseline), Visit 2 (Week 3 - post intervention 1) and Visit 3 (Week 8 - post intervention 2)
| Intervention | Visual Field Index % of normal vision (Mean) | ||
|---|---|---|---|
| Baseline (Visit 1) | Post Intervention 1 (Visit 2) | Post Intervention 2 (Visit 3) | |
| Dalfampridine Then Placebo | 77.53 | 78.50 | 79.71 |
| Placebo Then Dalfampridine | 85.38 | 86.65 | 86.00 |
10 reviews available for prednisone and Multiple Sclerosis
| Article | Year |
|---|---|
Sarcoidosis associated with Interferon beta treatment.
Topics: Anti-Inflammatory Agents; Erythema Nodosum; Female; Humans; Immunosuppressive Agents; Interferon bet | 2019 |
Sarcoidosis triggered by interferon-Beta treatment of multiple sclerosis: a case report and focused literature review.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Interferon-beta; Methotrexate; | 2012 |
Plasmapheresis, lymphocytapheresis, and immunosuppressive drug therapy in multiple sclerosis.
Topics: Acute Disease; Adrenocorticotropic Hormone; Adult; Antilymphocyte Serum; Azathioprine; Cell Separati | 1982 |
[Multiple sclerosis: diagnostic procedures and current therapeutic developments].
Topics: Brain; Diagnosis, Differential; Evoked Potentials, Somatosensory; Humans; Immunosuppressive Agents; | 1995 |
[New treatments for multiple sclerosis].
Topics: Anti-Inflammatory Agents; Cyclophosphamide; Humans; Immunosuppressive Agents; Interferon-beta; Multi | 1996 |
[Optic neuritis. First manifestation of multiple sclerosis? Current diagnostic and therapeutic strategies].
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Child; Diagnosis, Differential; Female; Fluorescein Ang | 2001 |
Effects of high-to-mega-dose synthetic corticosteroids on multiple sclerosis patients with special reference to cerebrospinal fluid antibodies to myelin basic protein.
Topics: Antibodies; Dose-Response Relationship, Drug; Humans; Methylprednisolone; Methylprednisolone Hemisuc | 1987 |
Hemiballism in multiple sclerosis.
Topics: Adult; Female; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Prednisone; Tetrabenazine; Th | 1988 |
Immunosuppressive therapy in neurological diseases.
Topics: Adrenocorticotropic Hormone; Azathioprine; Central Nervous System Diseases; Cyclophosphamide; Cytara | 1974 |
Adrenal steroid therapy in neurological disease. Part I.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Animals; Arteritis; Arthritis, Rheumatoid; Col | 1969 |
37 trials available for prednisone and Multiple Sclerosis
| Article | Year |
|---|---|
A randomized pilot trial of oral prednisone taper vs placebo following iv methylprednisolone for multiple sclerosis relapses: Effects on adrenal function and clinical efficacy.
Topics: Humans; Methylprednisolone; Multiple Sclerosis; Pilot Projects; Prednisone; Recurrence; Treatment Ou | 2021 |
Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis.
Topics: Anti-Inflammatory Agents; Atrophy; Cohort Studies; Cross-Sectional Studies; Female; Glatiramer Aceta | 2014 |
The optic neuritis treatment trial: a definitive answer and profound impact with unexpected results.
Topics: Administration, Oral; Glucocorticoids; Humans; Injections, Intravenous; Methylprednisolone; Multiple | 2008 |
Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial.
Topics: Acute Disease; Administration, Oral; Adult; Female; Glucocorticoids; Humans; Injections, Intravenous | 2008 |
Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort.
Topics: Adjuvants, Immunologic; Adolescent; Adrenal Cortex Hormones; Adult; Azathioprine; Brain; Cohort Stud | 2012 |
High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial.
Topics: Acute Disease; Adolescent; Adult; Anti-Inflammatory Agents; Brain; Cohort Studies; Female; Humans; M | 2003 |
Experience of the optic neuritis treatment trial.
Topics: Adolescent; Adult; Follow-Up Studies; Glucocorticoids; Humans; Methylprednisolone; Middle Aged; Mult | 2004 |
The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Area Under Curve; Biological Availability; Bi | 2004 |
Serum immunologic markers in multiple sclerosis patients on continuous combined therapy with beta-interferon 1a, prednisone and azathioprine.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Cytokines; Disability Evaluation; Drug Interactions; | 2006 |
Isoprinosine in multiple sclerosis treatment: a preliminary study.
Topics: Adult; Antibody Formation; Humans; Immunity, Cellular; Immunoglobulin G; Inosine; Inosine Pranobex; | 1982 |
High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton.
Topics: Administration, Oral; Adult; Aged; Bone and Bones; Calcitriol; Calcium; Female; Glomerular Filtratio | 1994 |
[Glucocorticoid treatment of acute optic neuritis and multiple sclerosis risk].
Topics: Acute Disease; Administration, Oral; Adult; Humans; Injections, Intravenous; Magnetic Resonance Imag | 1994 |
The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group.
Topics: Acute Disease; Administration, Oral; Adult; Drug Therapy, Combination; Female; Follow-Up Studies; Hu | 1993 |
The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial.
Topics: Cyclophosphamide; Double-Blind Method; Humans; Multiple Sclerosis; Physicians; Placebos; Plasma Exch | 1994 |
Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the optic neuritis treatment trial.
Topics: Acute Disease; Adolescent; Adult; Brain Diseases; Color Vision Defects; Contrast Sensitivity; Demyel | 1993 |
Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the optic neuritis treatment trial.
Topics: Acute Disease; Adolescent; Adult; Brain Diseases; Color Vision Defects; Contrast Sensitivity; Demyel | 1993 |
Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the optic neuritis treatment trial.
Topics: Acute Disease; Adolescent; Adult; Brain Diseases; Color Vision Defects; Contrast Sensitivity; Demyel | 1993 |
Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the optic neuritis treatment trial.
Topics: Acute Disease; Adolescent; Adult; Brain Diseases; Color Vision Defects; Contrast Sensitivity; Demyel | 1993 |
The Optic Neuritis Treatment Trial. Putting the results in perspective. The Optic Neuritis Study Group.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Drug Therapy, Combination; Female; Humans; In | 1995 |
The Optic Neuritis Treatment Trial. Putting the results in perspective. The Optic Neuritis Study Group.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Drug Therapy, Combination; Female; Humans; In | 1995 |
The Optic Neuritis Treatment Trial. Putting the results in perspective. The Optic Neuritis Study Group.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Drug Therapy, Combination; Female; Humans; In | 1995 |
The Optic Neuritis Treatment Trial. Putting the results in perspective. The Optic Neuritis Study Group.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Drug Therapy, Combination; Female; Humans; In | 1995 |
Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b.
Topics: Adolescent; Adult; Blood Cells; Female; Humans; Interferon-beta; Interferon-gamma; Male; Middle Aged | 1995 |
The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial.
Topics: Adult; Anti-Inflammatory Agents; Cohort Studies; Disability Evaluation; Disease Progression; Female; | 1997 |
Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group.
Topics: Administration, Oral; Adolescent; Adult; Cohort Studies; Color Perception; Contrast Sensitivity; Fem | 1997 |
Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group.
Topics: Administration, Oral; Adolescent; Adult; Cohort Studies; Color Perception; Contrast Sensitivity; Fem | 1997 |
Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group.
Topics: Administration, Oral; Adolescent; Adult; Cohort Studies; Color Perception; Contrast Sensitivity; Fem | 1997 |
Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group.
Topics: Administration, Oral; Adolescent; Adult; Cohort Studies; Color Perception; Contrast Sensitivity; Fem | 1997 |
Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group.
Topics: Administration, Oral; Adolescent; Adult; Cohort Studies; Color Perception; Contrast Sensitivity; Fem | 1997 |
Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group.
Topics: Administration, Oral; Adolescent; Adult; Cohort Studies; Color Perception; Contrast Sensitivity; Fem | 1997 |
Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group.
Topics: Administration, Oral; Adolescent; Adult; Cohort Studies; Color Perception; Contrast Sensitivity; Fem | 1997 |
Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group.
Topics: Administration, Oral; Adolescent; Adult; Cohort Studies; Color Perception; Contrast Sensitivity; Fem | 1997 |
Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group.
Topics: Administration, Oral; Adolescent; Adult; Cohort Studies; Color Perception; Contrast Sensitivity; Fem | 1997 |
Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Glucocorticoids; H | 1997 |
The effect of total lymphoid irradiation and low-dose steroids on T lymphocyte populations in multiple sclerosis: correlation with clinical and MRI status.
Topics: Adult; Double-Blind Method; Female; Glucocorticoids; Humans; Immunophenotyping; Lymphocyte Count; Ma | 1997 |
Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS.
Topics: Acetaminophen; Adjuvants, Immunologic; Adult; Analgesics, Non-Narcotic; Dose-Response Relationship, | 1998 |
Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction.
Topics: Acetaminophen; Administration, Oral; Adult; Analgesics, Non-Narcotic; Dose-Response Relationship, Dr | 1998 |
Prevention of corticosteroid-induced osteoporosis by alfacalcidol.
Topics: Adjuvants, Immunologic; Adult; Arthritis, Rheumatoid; Asthma; Bone Density; Calcium; Dose-Response R | 2000 |
The SKILL Card test in optic neuritis: experience of the Optic Neuritis Treatment Trial. Smith-Kettlewell Institute Low Luminance. Optic Neuritis Study Group.
Topics: Adolescent; Adult; Contrast Sensitivity; Female; Glucocorticoids; Health Status Indicators; Humans; | 2001 |
[Intensive immunosuppressive treatment of chronic progressive multiple sclerosis].
Topics: Activities of Daily Living; Chronic Disease; Clinical Trials as Topic; Cyclophosphamide; Drug Therap | 1978 |
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
Topics: Adult; Canada; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Drug Thera | 1991 |
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Color Perception; Female; Follow-Up Studies; | 1992 |
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Color Perception; Female; Follow-Up Studies; | 1992 |
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Color Perception; Female; Follow-Up Studies; | 1992 |
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Color Perception; Female; Follow-Up Studies; | 1992 |
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Color Perception; Female; Follow-Up Studies; | 1992 |
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Color Perception; Female; Follow-Up Studies; | 1992 |
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Color Perception; Female; Follow-Up Studies; | 1992 |
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Color Perception; Female; Follow-Up Studies; | 1992 |
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Color Perception; Female; Follow-Up Studies; | 1992 |
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Color Perception; Female; Follow-Up Studies; | 1992 |
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Color Perception; Female; Follow-Up Studies; | 1992 |
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Color Perception; Female; Follow-Up Studies; | 1992 |
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Color Perception; Female; Follow-Up Studies; | 1992 |
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Color Perception; Female; Follow-Up Studies; | 1992 |
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Color Perception; Female; Follow-Up Studies; | 1992 |
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Color Perception; Female; Follow-Up Studies; | 1992 |
[Effect of treatment with Encorton (Polfa), Solu-Medrol and Encorton and Cyclophosphamide and Encorton on the production of immunoglobulin G in the central nervous system in multiple sclerosis].
Topics: Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunoglobulin G; Met | 1989 |
Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy.
Topics: Administration, Oral; Adrenocorticotropic Hormone; Adult; Aged; Clinical Trials as Topic; Cyclophosp | 1987 |
Effect of cyclosporine on rubella virus-specific immune responses in chronic progressive multiple sclerosis.
Topics: Antibodies, Viral; Antibody Formation; Antigens, Viral; Chronic Disease; Cyclosporins; Drug Combinat | 1989 |
Therapeutic trials of multiple sclerosis and intrathecal IgG production.
Topics: Adrenocorticotropic Hormone; Albumins; Central Nervous System; Cyclophosphamide; Drug Therapy, Combi | 1986 |
[Results of the combined treatment of advanced multiple myeloma by the M-2 protocol: cyclophosphamide, vincristine, melphalan, nitrosourea and prednisone].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclopho | 1987 |
[Treatment of progressive and severe forms of multiple sclerosis using a combination of antilymphocyte serum, azathioprine and prednisone. Clinical and biological results. Comparison with a control group treated with azathioprine and prednisone only. 4-ye
Topics: Antilymphocyte Serum; Azathioprine; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up S | 1987 |
High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations.
Topics: Adult; Aged; Albumins; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Immunoglobulin | 1986 |
A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis.
Topics: Adult; Azathioprine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Double-B | 1985 |
Lymphocytes sensitised to basic encephalitogen in patients with multiple sclerosis unresponsive to steroid therapy.
Topics: Adrenocorticotropic Hormone; Autoantigens; Autoimmune Diseases; Brain; Cells, Cultured; Humans; Immu | 1974 |
143 other studies available for prednisone and Multiple Sclerosis
| Article | Year |
|---|---|
Acute infusion effects in relapsing multiple sclerosis patients receiving alemtuzumab under a modified prophylaxis regimen.
Topics: Alemtuzumab; Canada; Cytokines; Histamine H2 Antagonists; Humans; Methylprednisolone; Multiple Scler | 2022 |
Prednisone alleviates demyelination through regulation of the NLRP3 inflammasome in a C57BL/6 mouse model of cuprizone-induced demyelination.
Topics: Animals; Astrocytes; Corpus Callosum; Cuprizone; Cytokines; Demyelinating Diseases; Disease Models, | 2018 |
The first reported case of drug-induced hemolytic anemia caused by dimethyl fumarate in a patient with multiple sclerosis.
Topics: Adult; Anemia, Hemolytic; Blood Transfusion; Coombs Test; Dimethyl Fumarate; Female; Haptoglobins; H | 2019 |
Symptomatic sinus bradycardia after a treatment course of high-dose oral prednisone.
Topics: Administration, Oral; Arrhythmia, Sinus; Bradycardia; Female; Humans; Middle Aged; Multiple Sclerosi | 2013 |
Diagnostic and Therapeutic Challenges.
Topics: Acetazolamide; Administration, Oral; Adult; Diagnosis, Differential; Diuretics; Drug Therapy, Combin | 2016 |
Increased intracranial pressure in a case of pediatric multiple sclerosis.
Topics: Adolescent; Brain; Female; Humans; Immunoglobulin G; Interferon beta-1b; Interferon-beta; Intracrani | 2008 |
Pathological laughter in a patient with multiple sclerosis.
Topics: Brain Mapping; Follow-Up Studies; Humans; Laughter; Magnetic Resonance Imaging; Male; Middle Aged; M | 2008 |
Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis.
Topics: Adjuvants, Immunologic; Adult; Antibodies, Antinuclear; DNA; Female; Glucocorticoids; Humans; Interf | 2009 |
Recurrent pericarditis due to natalizumab treatment.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aspirin; Chest Pain; Colchicine; D | 2009 |
Ring and nodular multiple sclerosis lesions: a retrospective natural history study.
Topics: Adult; Anti-Inflammatory Agents; Contrast Media; Disability Evaluation; Disease Progression; Encepha | 2010 |
Optic neuritis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Frontal Lobe; Humans; Magnetic Resonance Imaging; Mu | 2010 |
Modified protocol for desensitization to glatiramer acetate.
Topics: Adult; Chemotherapy, Adjuvant; Clinical Protocols; Desensitization, Immunologic; Diphenhydramine; Dr | 2010 |
[Multiple evanescent white dot syndrome and multiple sclerosis].
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Brain; Chorioretinitis; Diplopia; Drug Therap | 2011 |
Hypereosinophilic syndrome with cardiac involvement in a pregnant patient with multiple sclerosis.
Topics: Adult; Anticoagulants; Arginine; Drug Substitution; Female; Glucocorticoids; Heparin; Humans; Hypere | 2011 |
Catastrophic demyelinating encephalomyelitis after intrathecal and intravenous stem cell transplantation in a patient with multiple sclerosis.
Topics: Adolescent; Anti-Inflammatory Agents; Cyclophosphamide; Encephalomyelitis, Acute Disseminated; Femal | 2012 |
[Clinical and experimental study on multiple sclerosis with bushen gusui tablet].
Topics: Adolescent; Adult; Animals; Drug Combinations; Drugs, Chinese Herbal; Encephalomyelitis, Autoimmune, | 2001 |
Progressive outer retinal necrosis in immunocompetent patients treated initially for optic neuropathy with systemic corticosteroids.
Topics: Acyclovir; Aged; Antiviral Agents; Aqueous Humor; Blindness; DNA, Viral; Drug Therapy, Combination; | 2003 |
[Metacortandracin in the treatment of disseminated sclerosis; clinical study of 56 cases].
Topics: Biomedical Research; Humans; Multiple Sclerosis; Prednisone; Psychotherapy, Multiple; Steroids | 1956 |
[Study of the plasma proteins in multiple sclerosis; attempted biological and clinical correlation in 63 cases, of which 30 have been treated with delta-cortisone for 2 years].
Topics: Blood Proteins; Cortisone; Humans; Multiple Sclerosis; Prednisone | 1958 |
For the treatment of multiple sclerosis with ACTH, cortisone and prednisone.
Topics: Adrenocorticotropic Hormone; Cortisone; Humans; Multiple Sclerosis; Prednisone | 1959 |
[MASSIVE CORTICOTHERAPY IN THE RECURRENT EPISODES OF MULTIPLE SCLEROSIS].
Topics: Humans; Multiple Sclerosis; Prednisone | 1963 |
NUTRITIONAL AND METABOLIC EFFECTS OF SOME NEWER STEROIDS. III. STANOZOLOL.
Topics: Amputation, Surgical; Anabolic Agents; Blood Chemical Analysis; Dexamethasone; Diabetic Neuropathies | 1964 |
[EXPERIENCES WITH CORTICOSTEROID TREATMENT OF MULTIPLE SCLEROSIS].
Topics: Adrenal Cortex Hormones; Cerebrospinal Fluid; Humans; Multiple Sclerosis; Prednisone | 1963 |
LARGE DOSE CORTICOSTEROID THERAPY OF EXPERIMENTAL AND HUMAN DEMYELINATING DISEASES.
Topics: Adrenal Cortex Hormones; Animals; Demyelinating Diseases; Drug Therapy; Encephalomyelitis; Encephalo | 1965 |
Remission of multiple sclerosis post-liver transplantation.
Topics: Female; Follow-Up Studies; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Liver Failur | 2004 |
The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Biological Availability; Central Nervous System; Cli | 2005 |
Effect of intravenous high-dose methylprednisolone on coagulation and fibrinolysis markers.
Topics: Adult; Aged; Anti-Inflammatory Agents; Blood Coagulation; Blood Coagulation Factors; Blood Coagulati | 2005 |
Iron and the folate-vitamin B12-methylation pathway in multiple sclerosis.
Topics: Adult; Anti-Inflammatory Agents; Black People; Dietary Fats; Dietary Supplements; Female; Folic Acid | 2006 |
Pathogenetic role of myelitis for syringomyelia.
Topics: Adult; Back Pain; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Methotrexate; | 2007 |
[Management of isolated optic neuritis in France: survey of neurologists and ophthalmologists].
Topics: Anti-Inflammatory Agents; Data Collection; Drug Utilization; France; Humans; Immunologic Factors; In | 2008 |
Submucous fibrosis of the mouth.
Topics: Adult; Diagnosis, Differential; Female; Humans; Hydrocortisone; Mouth Diseases; Mouth Mucosa; Multip | 1967 |
[Antibodies against encephalitogenic protein and myelin glycoprotein in the cerebrospinal fluid of patients with multiple sclerosis. Effect of encorton treatment on the autoantibody and immune complex levels].
Topics: Antigen-Antibody Complex; Autoantibodies; Autoimmune Diseases; Glycoproteins; Humans; Immunoglobulin | 1984 |
Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis.
Topics: Cyclophosphamide; Drug Therapy, Combination; Humans; Immunoglobulin G; Multiple Sclerosis; Prednison | 1980 |
Locus of selective depression of human natural killer cells by azathioprine.
Topics: Antibody-Dependent Cell Cytotoxicity; Azathioprine; Cell Communication; Cell Separation; Cytotoxicit | 1982 |
Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro. Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; B-Lymphocytes; Cell Line; Cytotoxicity, Immunologic; Female; Humans; I | 1982 |
Serum demyelinating factors in multiple sclerosis.
Topics: Animals; Blood; Cerebellum; Culture Media; Culture Techniques; Embryo, Mammalian; Female; Humans; Ma | 1983 |
The influence of disease activity on the number of blood cells of multiple sclerosis patients.
Topics: Adult; Azathioprine; Female; Granulocytes; Humans; Leukocyte Count; Lymphocytes; Male; Middle Aged; | 1984 |
Plasmapheresis with immunosuppressive drug therapy in progressive multiple sclerosis. A pilot study.
Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Scle | 1984 |
Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis.
Topics: Acute Disease; Adolescent; Adrenocorticotropic Hormone; Adult; Demyelinating Diseases; Dose-Response | 1980 |
Multiple sclerosis de novo CNS IgG synthesis: effect of ACTH and corticosteroids.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Aged; Central Nervous System; Dexametha | 1980 |
Multiple sclerosis de novo CNS IgG synthesis. Effect of CNS irradiation.
Topics: Adrenocorticotropic Hormone; Adult; Albumins; Central Nervous System; Cerebrospinal Fluid; Drug Ther | 1980 |
ACTH-induced cortisol production in multiple sclerosis.
Topics: Administration, Oral; Adrenocorticotropic Hormone; Dose-Response Relationship, Drug; Female; Humans; | 1981 |
Plasmapheresis in multiple sclerosis: preliminary findings.
Topics: Adult; Azathioprine; Drug Therapy, Combination; Female; Humans; Immune Complex Diseases; Immunoglobu | 1980 |
Corticosteroid therapy and periodontal disease.
Topics: Adolescent; Adult; Alveolar Process; Female; Gingival Diseases; Humans; Male; Middle Aged; Multiple | 1984 |
Intrathecal IgG synthesis and IgG index after intensive and chronic immunosuppressive treatment of multiple sclerosis.
Topics: Albumins; Cyclophosphamide; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Immuno | 1984 |
The influence of high-dose prednisone medication on autoantibody specific activity and on circulating immune complex level in cerebrospinal fluid of multiple sclerosis patients.
Topics: Adult; Antibody Formation; Antibody Specificity; Antigen-Antibody Complex; Autoantibodies; Female; H | 1983 |
Effect of high-dose intravenous steroid administration on contrast-enhancing computed tomographic scan lesions in multiple sclerosis.
Topics: Adult; Female; Humans; Injections, Intravenous; Iothalamate Meglumine; Male; Methylprednisolone; Mid | 1984 |
Coexistent manic symptoms and multiple sclerosis.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; | 1981 |
Cyclophosphamide levels in serum and spinal fluid of multiple sclerosis patients treated with immunosuppression.
Topics: Adult; Blood-Brain Barrier; Cyclophosphamide; Female; Humans; Immunoglobulin G; Immunosuppression Th | 1983 |
Multiple sclerosis.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Environment; Female; Humans; Immunoelectr | 1981 |
Atypical contrast enhancement in computed tomography of demyelinating disease.
Topics: Blood-Brain Barrier; Demyelinating Diseases; Dexamethasone; Humans; Multiple Sclerosis; Prednisone; | 1982 |
Plasmapheresis in multiple sclerosis: preliminary study.
Topics: Adult; Female; Humans; Immunoglobulin G; Male; Multiple Sclerosis; Plasmapheresis; Prednisone | 1980 |
[Clinical picture of transitional forms between multiple and diffuse sclerosis].
Topics: Adolescent; Arachnoiditis; Diagnostic Errors; Female; Humans; Multiple Sclerosis; Optic Chiasm; Opti | 1981 |
[Further experiences with the Imurek treatment in multiple sclerosis].
Topics: Azathioprine; Humans; Multiple Sclerosis; Prednisone; Premedication | 1981 |
Multiple sclerosis.
Topics: Adult; Diagnosis, Differential; Family Practice; Female; Humans; Multiple Sclerosis; Prednisone | 1980 |
Immunologic mechanisms in multiple sclerosis. Exacerbation by type A hepatitis and skin test antigens.
Topics: Acute Disease; Adult; Hemiplegia; Hepatitis A; Humans; Immunization; Immunoglobulin G; Male; Multipl | 1980 |
[Bullous pemphigoid and multiple sclerosis].
Topics: Follow-Up Studies; Humans; Male; Middle Aged; Multiple Sclerosis; Pemphigoid, Bullous; Prednisone; T | 1995 |
[Neuro-ophthalmology--new challenges].
Topics: Administration, Oral; Counseling; Humans; Methylprednisolone; Multiple Sclerosis; Optic Nerve Diseas | 1995 |
Correlation of myelin basic protein-like material in cerebrospinal fluid of multiple sclerosis patients with their response to glucocorticoid treatment.
Topics: Adult; Aged; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Male; Methylprednisol | 1993 |
Combination total lymphoid irradiation and low-dose corticosteroid therapy for progressive multiple sclerosis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lymphatic Irradiation; L | 1995 |
Follow-up study of MS patients treated with high-dose intravenous methylprednisolone.
Topics: Adult; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Immuno | 1994 |
What have the optic neuritis treatment trial and the longitudinal optic neuritis study shown us?
Topics: Administration, Oral; Clinical Trials as Topic; Cohort Studies; Follow-Up Studies; Humans; Injection | 1994 |
Corticosteroids, optic neuritis, and multiple sclerosis.
Topics: Humans; Methylprednisolone; Multiple Sclerosis; Optic Neuritis; Prednisone | 1994 |
The effect of large-dose prednisone therapy on IgG subclasses in multiple sclerosis.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme-Linked Immunosorbent A | 1994 |
Corticosteroids and optic neuritis.
Topics: Acute Disease; Anti-Inflammatory Agents; Bias; Humans; Methylprednisolone; Multiple Sclerosis; Optic | 1993 |
Increased generation of superoxide radicals in the blood of MS patients.
Topics: Adult; Erythrocytes; Female; Humans; Lipid Peroxidation; Male; Middle Aged; Multiple Sclerosis; Pred | 1993 |
High-dose corticosteroid regimen retards development of multiple sclerosis in optic neuritis treatment trial.
Topics: Acute Disease; Administration, Oral; Drug Administration Schedule; Humans; Incidence; Injections, In | 1994 |
Megadose corticosteroids in multiple sclerosis.
Topics: Adrenal Cortex Hormones; Brain; Clinical Trials as Topic; Cohort Studies; Humans; Injections, Intrav | 1994 |
Corticosteroids and optic neuritis.
Topics: Administration, Oral; Adolescent; Adrenocorticotropic Hormone; Child; Female; Humans; Male; Methylpr | 1993 |
Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.
Topics: Adult; Brain; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Methylprednisolone; M | 1993 |
Pemoline-induced autoimmune hepatitis.
Topics: Antibodies, Antinuclear; Autoantibodies; Autoimmune Diseases; Central Nervous System Stimulants; Che | 1996 |
IL-10 production in multiple sclerosis patients, SLE patients and healthy controls: preliminary findings.
Topics: Adult; Aged; Case-Control Studies; Female; Humans; Interleukin-10; Leukocytes, Mononuclear; Lupus Er | 1997 |
Multiple sclerosis, the great masquerader: an atypical ocular presentation.
Topics: Administration, Oral; Adult; Brain; Chronic Disease; Female; Follow-Up Studies; Glucocorticoids; Hum | 1997 |
Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon beta-1b in patients with relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Adult; Case-Control Studies; Female; Glucocorticoids; Humans; Incidence; Injec | 1998 |
Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Cell Membrane Permeability; Cost-Benefit Anal | 1999 |
Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS.
Topics: Acetaminophen; Drug Administration Schedule; Fever; Humans; Hypothalamus; Ibuprofen; Interferon beta | 2000 |
Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Optic Neuritis Study Group.
Topics: Administration, Oral; Adult; Alleles; Brain; Drug Therapy, Combination; Female; Haplotypes; HLA-DR2 | 2000 |
Postpartum optic neuritis: etiologic and pathophysiologic considerations.
Topics: Adult; Brain; Female; Glucocorticoids; Humans; Magnetic Resonance Imaging; Methylprednisolone; Multi | 2000 |
Susac's syndrome: beneficial effects of corticosteroid therapy in a Japanese case.
Topics: Adult; Anti-Inflammatory Agents; Asian People; Asthma; Ataxia; Brain; Cognition Disorders; Confusion | 2001 |
The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. 1994 [classical article].
Topics: Cyclophosphamide; Female; History, 20th Century; Humans; Male; Multiple Sclerosis; Neurologic Examin | 2001 |
The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. 1997.
Topics: Female; History, 20th Century; Humans; Male; Methylprednisolone; Multiple Sclerosis; Optic Neuritis; | 2001 |
Schemes to eradicate the multiple sclerosis central nervous system immune reaction.
Topics: Adrenocorticotropic Hormone; Central Nervous System; Drug Therapy, Combination; Humans; Immunoglobul | 1976 |
Hoquet diabolique: intractable hiccups as a manifestation of multiple sclerosis.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Carbamazepine; Female; Hiccup; Humans; Male; Multipl | 1979 |
Active multiple sclerosis. Enhanced computerized tomographic imaging of lesions and the effect of corticosteroids.
Topics: Adult; Brain; Capillary Permeability; Female; Glucocorticoids; Humans; Multiple Sclerosis; Prednison | 1978 |
[Aspects of immunosuppressive therapy of multiple sclerosis].
Topics: Cyclophosphamide; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Multiple Sclerosis; P | 1975 |
Spontaneous and PHA stimulated lymphocyte transformation in multiple sclerosis patients during and after acute exacerbations with special reference to steroid therapy.
Topics: Female; Humans; Idoxuridine; Lectins; Lymphocyte Activation; Male; Multiple Sclerosis; Prednisone; T | 1977 |
The effect of intensive immunosuppression on the in vitro activity of lymphocytes from multiple sclerosis patients.
Topics: Antilymphocyte Serum; Azathioprine; Cells, Cultured; Histocompatibility Testing; Humans; Immunosuppr | 1976 |
Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone.
Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immunoglobulin G; Male; Middle A | 1975 |
Intensive immunosuppression in patients with disseminated sclerosis. III. Lymphocyte response in vitro.
Topics: Antilymphocyte Serum; Azathioprine; Histocompatibility Testing; Humans; Immunosuppression Therapy; I | 1975 |
Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response.
Topics: Adrenal Cortex Hormones; Adult; Anaphylaxis; Animals; Antilymphocyte Serum; Azathioprine; Female; Fo | 1975 |
[Immunosuppressive treatment in multiple sclerosis].
Topics: Adolescent; Adult; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 1992 |
Neurogenic pulmonary edema: a presenting symptom in multiple sclerosis.
Topics: Adolescent; Female; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Prednisone; Pulmonary Ed | 1992 |
Evidence for increased lipid peroxidation in multiple sclerosis.
Topics: Breath Tests; Ethane; Female; Free Radicals; Humans; Lipid Peroxidation; Male; Multiple Sclerosis; P | 1992 |
Corticosteroids in the treatment of optic neuritis.
Topics: Humans; Multiple Sclerosis; Optic Neuritis; Prednisone; Recurrence | 1992 |
Uhthoff's symptom in optic neuritis: relationship to magnetic resonance imaging and development of multiple sclerosis.
Topics: Acute Disease; Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Brain; Child; Evoked Potentials | 1991 |
Cyclophosphamide and plasma exchange in multiple sclerosis.
Topics: Cyclophosphamide; Humans; Multiple Sclerosis; Plasma Exchange; Prednisone; Research Design; Severity | 1991 |
Serum soluble interleukin-2 receptor levels in chronic progressive, stable and steroid-treated multiple sclerosis.
Topics: Adult; Aged; Disability Evaluation; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Nervous S | 1991 |
Adrenal function after corticosteroid treatment in MS.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Dose-Response Relationship, Drug; Humans; Hydr | 1991 |
Assessment of the hypothalamic-pituitary-adrenal axis function after corticosteroid therapy for MS relapses.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Cortodoxone; Female; Humans; Hydrocortisone; Hypotha | 1990 |
Bullous pemphigoid and multiple sclerosis.
Topics: Adult; Humans; Male; Multiple Sclerosis; Pemphigoid, Bullous; Prednisone; Skin Diseases, Vesiculobul | 1990 |
[Multiple sclerosis with early manifestation in children].
Topics: Adolescent; Child; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Male; Multiple Sclero | 1990 |
Suppression of the immune reaction in multiple sclerosis might be achieved by intravenous injections of myelin basic protein, concomitant with the administration of an immunosuppressant and a corticosteroid.
Topics: Autoimmune Diseases; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Humans; Im | 1988 |
Suppression of the immune reaction in multiple sclerosis might be achieved by intravenous injections of myelin basic protein, concomitant with the administration of an immunosuppressant and a corticosteroid.
Topics: Animals; Autoimmune Diseases; Azathioprine; Disease Models, Animal; Drug Therapy, Combination; Encep | 1988 |
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
Topics: Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunoglobulin G; Intervertebral D | 1988 |
Effect of immunosuppressive therapy on humoral immune response in multiple sclerosis.
Topics: Antibody Formation; Antigen-Antibody Complex; Complement C1q; Cyclophosphamide; Gangliosides; Humans | 1989 |
[Morphological and functional condition of the stomach in multiple sclerosis patients treated with prednisone].
Topics: Adult; Gastric Juice; Gastric Mucosa; Gastritis; Humans; Middle Aged; Multiple Sclerosis; Prednisone | 1989 |
[Present possibilities in the therapy of multiple sclerosis].
Topics: Adrenocorticotropic Hormone; Glucocorticoids; Humans; Immunosuppressive Agents; Multiple Sclerosis; | 1987 |
Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis.
Topics: Adrenocorticotropic Hormone; Adult; Bipolar Disorder; Female; Humans; Male; Multiple Sclerosis; Pred | 1988 |
Effect of corticoid treatment upon the measles virus-induced leukocyte adherence inhibition.
Topics: Adrenal Cortex Hormones; Adult; Dose-Response Relationship, Drug; Female; Humans; Leukocyte Adherenc | 1987 |
Azathioprine and steroids are not more effective in decreasing multiple sclerosis intra-blood-brain-barrier IgG synthesis than steroids alone.
Topics: Adrenocorticotropic Hormone; Azathioprine; Blood-Brain Barrier; Drug Therapy, Combination; Humans; I | 1985 |
Indications of the occurrence of inflammatory reactions in the clinical improvement phase in multiple sclerosis patients.
Topics: Adrenocorticotropic Hormone; Adult; Biological Products; Central Nervous System; Cytokines; Female; | 1985 |
Immunological treatment of multiple sclerosis. II.
Topics: Adrenocorticotropic Hormone; Azathioprine; Cyclophosphamide; Cyclosporins; Humans; Immunosuppression | 1986 |
Appearance of Guillain-Barré syndrome in patients during corticosteroid treatment.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Aged; Colitis, Ulcerative; Dexamethasone; Fema | 1986 |
Amenorrhea after immunosuppressive treatment of multiple sclerosis.
Topics: Adult; Amenorrhea; Cyclophosphamide; Estradiol; Female; Follicle Stimulating Hormone; Humans; Immuno | 1987 |
Effect of lymphoid irradiation on clinical course, lymphocyte count, and T-cell subsets in chronic progressive multiple sclerosis.
Topics: Double-Blind Method; Humans; Leukocyte Count; Lymphoid Tissue; Multiple Sclerosis; Prednisone; T-Lym | 1988 |
Multiple sclerosis, euthyroid restrictive Grave's ophthalmopathy, and myasthenia gravis. A case report.
Topics: Blepharoptosis; Diplopia; Graves Disease; Humans; Injections; Male; Methylprednisolone; Methylpredni | 1988 |
Primary Sjögren's syndrome with central nervous system disease mimicking multiple sclerosis.
Topics: Adult; Age Factors; Central Nervous System Diseases; Diagnosis, Differential; Female; Humans; Male; | 1986 |
The effect of oral corticosteroid dosage on CT enhancing multiple sclerosis plaques.
Topics: Administration, Oral; Adolescent; Adult; Brain; Female; Humans; Male; Middle Aged; Multiple Sclerosi | 1985 |
Natural killer cell activity in multiple sclerosis and myasthenia gravis.
Topics: Adult; Female; Humans; In Vitro Techniques; Killer Cells, Natural; Male; Multiple Sclerosis; Myasthe | 1985 |
Myasthenia gravis and multiple sclerosis: an unusual combination of diseases.
Topics: Adult; Brain; Demyelinating Diseases; Diplopia; Edrophonium; Electroencephalography; Female; gamma-G | 1974 |
[Catamnestic studies of the results of rehabilitation of patients with multiple sclerosis].
Topics: Adrenocorticotropic Hormone; Adult; Disability Evaluation; Female; Follow-Up Studies; Hospitalizatio | 1971 |
Subacute demyelinating disease in an adult (diffuse-disseminated sclerosis).
Topics: Adrenocorticotropic Hormone; Adult; Cephalothin; Chloramphenicol; Dexamethasone; Female; Gentamicins | 1971 |
Optic neuritis and its relationship to disseminated sclerosis.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Age Factors; Australia; Child; Child, Preschool; Dex | 1970 |
[50th contribution of the Central Expert Committee for Drug Trade, Section Human Medicine].
Topics: Adrenocorticotropic Hormone; Antilymphocyte Serum; Azathioprine; Cyclophosphamide; Humans; Multiple | 1973 |
Multiple sclerosis: an overview, with some observations on the spinal fluid protein.
Topics: Adrenocorticotropic Hormone; Adult; Female; Humans; Immunoglobulin G; Male; Multiple Sclerosis; Pred | 1974 |
[Critic study of multiple sclerosis treatment by chlorambucil and intraspinal corticotherapy. Apropos of 100 cases followed up from 2 to 9 years].
Topics: Acetates; Adrenocorticotropic Hormone; Adult; Amenorrhea; Chlorambucil; Female; Follow-Up Studies; H | 1973 |
[Therapy of multiple sclerosis].
Topics: Adrenocorticotropic Hormone; Combined Modality Therapy; Cortisone; Follow-Up Studies; Humans; Multip | 1966 |
[Acute renal failure due to acute adrenocortical failure following steroid treatment].
Topics: Acute Disease; Acute Kidney Injury; Adrenal Gland Diseases; Adult; Female; Humans; Multiple Sclerosi | 1973 |
Optic neuritis in systemic lupus erythematosus.
Topics: Adult; Child; Diagnostic Errors; Eye Manifestations; Female; Humans; Lupus Erythematosus, Systemic; | 1974 |
Reactivities to horse anti-lymphocyte globulin. I. Induction of immunologic tolerance in man.
Topics: Animals; Antibody Formation; Antilymphocyte Serum; Azathioprine; Fever; Hemagglutination Tests; Hors | 1970 |
Reactivities to horse anti-lymphocyte globulin. II. Serum sickness nephritis with complement alterations in man.
Topics: Antilymphocyte Serum; Azathioprine; Complement System Proteins; Fever; Glomerulonephritis; Hemagglut | 1970 |
Five year follow-up study of sixty cases of inflammatory diseases treated with alternate day corticosteroid therapy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Arthritis, Rheumatoid; Asthma; Autoimmune Diseases; C | 1972 |
Lymphotoxic activity in multiple sclerosis serum.
Topics: Blood Cell Count; Cytotoxicity Tests, Immunologic; Humans; Lectins; Lymphocyte Activation; Lymphocyt | 1971 |
The effect of a lymphotoxic factor in the sera of patients with multiple sclerosis and acute leukemia on the metabolism of normal and leukemic lymphocytes.
Topics: Adolescent; Adult; Child; Child, Preschool; Culture Techniques; Depression, Chemical; Female; Humans | 1971 |
[Experiences with immunosuppressive treatment of multiple sclerosis].
Topics: Autoimmune Diseases; Cyclophosphamide; Humans; Immunosuppressive Agents; Multiple Sclerosis; Prednis | 1971 |
[Electrophoresis of cerebrospinal fluid in multiple sclerosis depending on the clinical form, duration of the disease and the treatment].
Topics: Adolescent; Adult; Cerebrospinal Fluid; Electrophoresis, Paper; Female; Humans; Male; Middle Aged; M | 1971 |
[Myasthenia gravis. Some clinical aspects].
Topics: Adolescent; Adult; Aged; Autopsy; Child; Diagnosis, Differential; Electromyography; Eye Manifestatio | 1971 |
The long-term treatment of multiple sclerosis with corticoids.
Topics: Cortisone; Dexamethasone; Female; Humans; Male; Multiple Sclerosis; Prednisone; Prognosis; Statistic | 1965 |
Peripheral uveitis in patients with multiple sclerosis.
Topics: Adolescent; Adult; Female; Glucocorticoids; Humans; Intraocular Pressure; Male; Methylprednisolone; | 1970 |
[Diagnostic accuracy in multiple sclerosis].
Topics: Adult; Anti-Bacterial Agents; Female; Humans; Multiple Sclerosis; Prednisone | 1970 |
Transient facial myokymia. An uncommon manifestation of multiple sclerosis.
Topics: Adult; Brain Neoplasms; Electromyography; Facial Muscles; Female; Humans; Medulla Oblongata; Multipl | 1969 |
[Critical evaluation of prednisone treatment of multiple sclerosis in comparison with various other therapeutic methods].
Topics: Adolescent; Adult; Humans; Middle Aged; Multiple Sclerosis; Prednisone | 1965 |
[Experiences in prednisone treatment of multiple sclerosis as compared to other therapeutic methods (preliminary report)].
Topics: Adolescent; Adult; Ethyl Biscoumacetate; Female; Histamine; Humans; Iontophoresis; Male; Middle Aged | 1965 |